Inhibikase Therapeutics (IKT) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

IKT · Stock Price

USD 1.99-0.01 (-0.50%)

Market Cap: $264.1M

Historical price data

Market Cap: $264.1MFounded: 2008HQ: Atlanta, United States

Sector Ranking#243 in Small Molecule Drugs

Overview

Inhibikase Therapeutics is a clinical-stage biotech focused on developing selective kinase inhibitors, with its lead candidate IkT-001 targeting pulmonary arterial hypertension (PAH). The company's strategy is to improve upon the proven efficacy of imatinib in PAH by designing a molecule with a superior safety and tolerability profile. Led by a seasoned management team with deep cardiovascular and biopharmaceutical experience, Inhibikase is advancing its Phase 2 IMPROVE-PAH trial. The company went public via a SPAC merger in 2021 and is positioned in a high-need orphan disease market with significant unmet medical need.

Cardiopulmonary DiseasePulmonary Arterial Hypertension

Technology Platform

Platform for the rational design and development of selective small molecule kinase inhibitors, aiming to improve therapeutic windows by minimizing off-target effects compared to earlier generation inhibitors.

Funding History

3

Total raised:$30.5M

PIPE$10MUndisclosedDec 15, 2021

IPO$15MUndisclosedOct 7, 2020

Series A$5.5MUndisclosedJun 15, 2019

Opportunities

IkT-001 addresses a high unmet need in PAH, an orphan disease with a poor prognosis and a multi-billion dollar market.

The drug's design, based on the validated efficacy of imatinib but with a potentially improved safety profile, positions it as a promising disease-modifying candidate in a treatment landscape that is beginning to shift beyond symptomatic care.

Risk Factors

The company faces high clinical risk as its value is concentrated in a single Phase 2 asset.

It must prove IkT-001's safety and efficacy superiority over imatinib and compete in a market being reshaped by new therapies like sotatercept.

As a pre-revenue company, it is also dependent on successful capital raises, which can be dilutive.

Competitive Landscape

Inhibikase competes in the PAH market against established vasodilator therapies from companies like United Therapeutics and Johnson & Johnson, and against novel disease-modifying agents, most notably Merck's sotatercept. IkT-001's differentiation hinges on its oral administration and targeted mechanism against PDGFR-driven vascular remodeling, aiming to offer a better-tolerated alternative to imatinib's proven efficacy.